Ken Mayer’s Electrome and BioElectronics Corp (BIEL) are evolving the vagus nerve stimulation (VNS) concepts featured in the current edition of AARP magazine article entitled "You've Got Some Nerve - Stimulation of the Vagus Nerve may be the answer for chronic pain, heart disease, depression and more".
The "Brain" for the Hardware: While BIEL provides the wearable patches (hardware), Ken Mayer’s Electrome provides the "bioelectric code" (software). This partnership aims to turn simple electrical pulses into precise instructions that can target the vagus nerve more effectively.
Non-Invasive "VNS": AARP highlights surgical implants for VNS, but Mayer and BIEL are focused on transcutaneous (through-the-skin) stimulation. This offers the same neurological benefits—like reducing inflammation or improving mood—without the risks or costs of surgery.
AI-Optimized Therapy: Unlike the "one-size-fits-all" pulses mentioned in traditional studies, Mayer’s Dual Discovery Engine uses AI to customize the electrical signal. This could allow a BIEL device to automatically adjust its output if it senses the user is under high stress or experiencing an inflammatory flare-up.
Pathogen Interference (LymeCure™): In a 2026 breakthrough, Mayer launched the LymeCure™ study with Tulane University. This explores using bioelectric signals to physically disrupt pathogens like Lyme disease, moving the "vagus nerve" conversation from simple relaxation into active infection-fighting.
Targeting "Mental Health" Without Pills: Aligning with AARP’s focus on depression, the BIEL/Electrome alliance is researching how their non-thermal electromagnetic energy can modulate neurotransmitters like serotonin, potentially offering a wearable alternative for treatment-resistant depression.
Consumer Accessibility: While the medical devices in the AARP article are restricted to hospital settings, the BIEL/Electrome model is built for the Over-the-Counter (OTC) market. This makes advanced neuromodulation available for home use at a fraction of the price of clinical VNS.
The "Brain" for the Hardware: While BIEL provides the wearable patches (hardware), Ken Mayer’s Electrome provides the "bioelectric code" (software). This partnership aims to turn simple electrical pulses into precise instructions that can target the vagus nerve more effectively.
Non-Invasive "VNS": AARP highlights surgical implants for VNS, but Mayer and BIEL are focused on transcutaneous (through-the-skin) stimulation. This offers the same neurological benefits—like reducing inflammation or improving mood—without the risks or costs of surgery.
AI-Optimized Therapy: Unlike the "one-size-fits-all" pulses mentioned in traditional studies, Mayer’s Dual Discovery Engine uses AI to customize the electrical signal. This could allow a BIEL device to automatically adjust its output if it senses the user is under high stress or experiencing an inflammatory flare-up.
Pathogen Interference (LymeCure™): In a 2026 breakthrough, Mayer launched the LymeCure™ study with Tulane University. This explores using bioelectric signals to physically disrupt pathogens like Lyme disease, moving the "vagus nerve" conversation from simple relaxation into active infection-fighting.
Targeting "Mental Health" Without Pills: Aligning with AARP’s focus on depression, the BIEL/Electrome alliance is researching how their non-thermal electromagnetic energy can modulate neurotransmitters like serotonin, potentially offering a wearable alternative for treatment-resistant depression.
Consumer Accessibility: While the medical devices in the AARP article are restricted to hospital settings, the BIEL/Electrome model is built for the Over-the-Counter (OTC) market. This makes advanced neuromodulation available for home use at a fraction of the price of clinical VNS.
1
